Justin Ford - Revance Therapeutics, VP People
| RVNCDelisted Stock | USD 3.65 0.00 0.00% |
Insider
Justin Ford is VP People of Revance Therapeutics,
| Phone | 615 724 7755 |
| Web | https://www.revance.com |
Revance Therapeutics, Management Efficiency
The company has return on total asset (ROA) of (0.2436) % which means that it has lost $0.2436 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.9678) %, meaning that it created substantial loss on money invested by shareholders. Revance Therapeutics,'s management efficiency ratios could be used to measure how well Revance Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities.Revance Therapeutics, currently holds 478.43 M in liabilities with Debt to Equity (D/E) ratio of 2.94, implying the company greatly relies on financing operations through barrowing. Revance Therapeutics, has a current ratio of 3.31, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Revance Therapeutics,'s use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Dean MD | Pliant Therapeutics | N/A | |
| Debra Nielsen | Immunocore Holdings | N/A | |
| Margaret MBA | Amylyx Pharmaceuticals | 59 | |
| Rebecca MD | Madrigal Pharmaceuticals | 73 | |
| Hal MD | Pliant Therapeutics | N/A | |
| Prof Shair | Nuvalent | 56 | |
| Federico MD | Apellis Pharmaceuticals | 50 | |
| Michelle Gilson | Arcellx | 32 | |
| Martin MD | Ventyx Biosciences | 49 | |
| William JD | Akero Therapeutics | 51 | |
| Cedric MD | Apellis Pharmaceuticals | 53 | |
| Rohan Palekar | 89bio Inc | 59 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| Timothy Rolph | Akero Therapeutics | 71 | |
| Rami Elghandour | Arcellx | 46 | |
| John Nuss | Ventyx Biosciences | 66 | |
| Clayton Robertson | Immunocore Holdings | N/A | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| Christopher MD | Arcellx | 45 | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
Management Performance
| Return On Equity | -20.97 | |||
| Return On Asset | -0.24 |
Revance Therapeutics, Leadership Team
Elected by the shareholders, the Revance Therapeutics,'s board of directors comprises two types of representatives: Revance Therapeutics, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Revance. The board's role is to monitor Revance Therapeutics,'s management team and ensure that shareholders' interests are well served. Revance Therapeutics,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Revance Therapeutics,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dwight JD, Chief Counsel | ||
| Dustin Sjuts, Vice President of Strategy and Sales | ||
| Conor Gallagher, Head Aesthetics | ||
| Jeanie Herbert, Sr. Director of Investor Relations | ||
| Mark Foley, CEO Director | ||
| Erica Jordan, Chief Officer | ||
| Azita Nejad, VP Operations | ||
| Dwight Moxie, Chief Counsel | ||
| Justin Ford, VP People | ||
| Amie Krause, Chief Officer | ||
| MD MBA, Chief Officer | ||
| Jessica Serra, Head ESG | ||
| Aubrey Rankin, Consultant | ||
| Tobin Schilke, CFO and Principal Financial Officer | ||
| Taryn Conway, Vice President of Marketing |
Revance Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Revance Therapeutics, a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -20.97 | |||
| Return On Asset | -0.24 | |||
| Profit Margin | (0.72) % | |||
| Operating Margin | (0.54) % | |||
| Current Valuation | 680.39 M | |||
| Shares Outstanding | 104.39 M | |||
| Shares Owned By Insiders | 8.55 % | |||
| Shares Owned By Institutions | 87.45 % | |||
| Number Of Shares Shorted | 4.51 M | |||
| Price To Earning | (7.60) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Revance Stock
If you are still planning to invest in Revance Therapeutics, check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance Therapeutics,'s history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |